Details of the Drug

General Information of Drug (ID: DMJX6ZG)

Drug Name
Codeine
Synonyms
codeine; Methylmorphine; Codeine anhydrous; Codicept; l-Codeine; Coducept; Morphine monomethyl ether; Morphine 3-methyl ether; 76-57-3; (-)-Codeine; O3-Methylmorphine; codeinum; Morphine-3-methyl ether; Codein; Norcodine, N-methyl; Norcodeine, N-methyl; CODEINE BASE; Codeine polistirex; codeina; O(3)-methylmorphine; CCRIS 7555; Morphine-3-methyl ester; HSDB 3043; UNII-UX6OWY2V7J; CHEBI:16714; EINECS 200-969-1; UX6OWY2V7J; Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-; Codeine Anhydrate
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1], [2]
Cough MD12 Phase 1 [1], [3]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 299.4
Topological Polar Surface Area (xlogp) 1.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The renal clearance of drug is 183 +/- 59 mL/min [5]
Elimination
About 90% of the total dose of codeine is excreted by the kidneys [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 hours [7]
Metabolism
The drug is metabolized via the liver [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.04248 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.7% [9]
Vd
The volume of distribution (Vd) of drug is 3-6 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 435 mg/mL [4]
Chemical Identifiers
Formula
C18H21NO3
IUPAC Name
(4R,4aR,7S,7aR,12bS)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-ol
Canonical SMILES
CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
InChIKey
OROGSEYTTFOCAN-DNJOTXNNSA-N
Cross-matching ID
PubChem CID
5284371
ChEBI ID
CHEBI:16714
CAS Number
76-57-3
DrugBank ID
DB00318
TTD ID
D03DIG
VARIDT ID
DR00055
INTEDE ID
DR0366
ACDINA ID
D00148

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor delta (OPRD1) TT27RFC OPRD_HUMAN Agonist [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [14]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [15]
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [16]
UDP-glucuronosyltransferase 2B4 (UGT2B4)
Main DME 		DENUPDX UD2B4_HUMAN Substrate [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pain
ICD Disease Classification MG30-MG3Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor delta (OPRD1) DTT OPRD1 5.52E-01 0.03 0.23
Organic cation transporter 1 (SLC22A1) DTP SLC22A1 5.15E-01 1.61E-02 7.93E-02
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.87E-01 4.98E-02 3.61E-01
UDP-glucuronosyltransferase 2B4 (UGT2B4) DME UGT2B4 7.18E-01 -1.35E-02 -1.36E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Codeine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Codeine and Pentazocine. Pain [MG30-MG3Z] [78]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Codeine and Dextropropoxyphene. Pain [MG30-MG3Z] [79]
Butorphanol DM5KYPJ Major Additive hypotensive effects by the combination of Codeine and Butorphanol. Pain [MG30-MG3Z] [78]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Codeine and Oxymorphone. Pain [MG30-MG3Z] [80]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Codeine and Levorphanol. Pain [MG30-MG3Z] [80]
Hydromorphone DMHP21E Major Additive CNS depression effects by the combination of Codeine and Hydromorphone. Pain [MG30-MG3Z] [80]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Codeine and Dezocine. Pain [MG30-MG3Z] [78]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Codeine and Flavoxate. Pain [MG30-MG3Z] [81]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Codeine and Nalbuphine. Pain [MG30-MG3Z] [78]
Buprenorphine DMPRI8G Major Additive hypotensive effects by the combination of Codeine and Buprenorphine. Pain [MG30-MG3Z] [78]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Codeine and Hydrocodone. Pain [MG30-MG3Z] [80]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Codeine and Meperidine. Pain [MG30-MG3Z] [80]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Codeine and Oxycodone. Pain [MG30-MG3Z] [80]
⏷ Show the Full List of 13 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Codeine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Codeine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [82]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Codeine and Oliceridine. Acute pain [MG31] [80]
Chlorzoxazone DMCYVDT Major Additive CNS depression effects by the combination of Codeine and Chlorzoxazone. Acute pain [MG31] [80]
Scopolamine DMOM8AL Moderate Additive antimotility effects by the combination of Codeine and Scopolamine. Addictive disorder [6C50-6C5Z] [81]
Mitotane DMU1GX0 Moderate Increased metabolism of Codeine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [83]
Galantamine DMEO794 Moderate Decreased metabolism of Codeine caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [84]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Codeine caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [85]
Buspirone DMBS632 Major Additive CNS depression effects by the combination of Codeine and Buspirone. Anxiety disorder [6B00-6B0Z] [80]
Clorazepate DMC3JST Major Additive CNS depression effects by the combination of Codeine and Clorazepate. Anxiety disorder [6B00-6B0Z] [86]
Alprazolam DMC7XDN Major Additive CNS depression effects by the combination of Codeine and Alprazolam. Anxiety disorder [6B00-6B0Z] [80]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Codeine and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [86]
Hydroxyzine DMF8Y74 Major Additive CNS depression effects by the combination of Codeine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [80]
Halazepam DMPFWO6 Major Additive CNS depression effects by the combination of Codeine and Halazepam. Anxiety disorder [6B00-6B0Z] [80]
Chlordiazepoxide DMTN5XI Major Additive CNS depression effects by the combination of Codeine and Chlordiazepoxide. Anxiety disorder [6B00-6B0Z] [80]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Codeine and Chlormezanone. Anxiety disorder [6B00-6B0Z] [80]
Clobazam - Lundbeck DMW1OQ0 Major Additive CNS depression effects by the combination of Codeine and Clobazam - Lundbeck. Anxiety disorder [6B00-6B0Z] [80]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Codeine and Oxazepam. Anxiety disorder [6B00-6B0Z] [80]
Promazine DMZAL7W Major Additive CNS depression effects by the combination of Codeine and Promazine. Appearance/behaviour symptom [MB23] [80]
Desipramine DMT2FDC Moderate Additive serotonergic effects by the combination of Codeine and Desipramine. Attention deficit hyperactivity disorder [6A05] [87]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Codeine and Cariprazine. Bipolar disorder [6A60] [80]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Codeine and Loperamide. Bowel habit change [ME05] [82]
Secobarbital DM14RF5 Major Additive CNS depression effects by the combination of Codeine and Secobarbital. Chronic insomnia [7A00] [80]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Codeine and Dihydrocodeine. Chronic pain [MG30] [86]
Levomilnacipran DMV26S8 Moderate Additive serotonergic effects by the combination of Codeine and Levomilnacipran. Chronic pain [MG30] [87]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Codeine and Olopatadine. Conjunctiva disorder [9A60] [88]
Propofol DMB4OLE Moderate Additive cardiorespiratory depression effects by the combination of Codeine and Propofol. Corneal disease [9A76-9A78] [89]
Methadone DMTW6IU Major Additive CNS depression effects by the combination of Codeine and Methadone. Cough [MD12] [80]
Dextromethorphan DMUDJZM Moderate Additive serotonergic effects by the combination of Codeine and Dextromethorphan. Cough [MD12] [87]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Codeine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [83]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Codeine and Ethanol. Cystitis [GC00] [90]
Trimipramine DM1SC8M Moderate Additive serotonergic effects by the combination of Codeine and Trimipramine. Depression [6A70-6A7Z] [87]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Codeine and Cyclobenzaprine. Depression [6A70-6A7Z] [80]
Imipramine DM2NUH3 Moderate Additive serotonergic effects by the combination of Codeine and Imipramine. Depression [6A70-6A7Z] [87]
Nortriptyline DM4KDYJ Moderate Additive serotonergic effects by the combination of Codeine and Nortriptyline. Depression [6A70-6A7Z] [87]
Vilazodone DM4LECQ Moderate Additive serotonergic effects by the combination of Codeine and Vilazodone. Depression [6A70-6A7Z] [87]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Codeine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [91]
Paroxetine DM5PVQE Moderate Decreased metabolism of Codeine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [85]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Codeine and Selegiline. Depression [6A70-6A7Z] [92]
Vortioxetine DM6F1PU Moderate Additive serotonergic effects by the combination of Codeine and Vortioxetine. Depression [6A70-6A7Z] [87]
Duloxetine DM9BI7M Moderate Decreased metabolism of Codeine caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [85]
Milnacipran DMBFE74 Moderate Additive serotonergic effects by the combination of Codeine and Milnacipran. Depression [6A70-6A7Z] [87]
Escitalopram DMFK9HG Moderate Decreased metabolism of Codeine caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [85]
Desvenlafaxine DMHD4PE Moderate Additive serotonergic effects by the combination of Codeine and Desvenlafaxine. Depression [6A70-6A7Z] [87]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Codeine and OPC-34712. Depression [6A70-6A7Z] [80]
Clomipramine DMINRKW Moderate Additive serotonergic effects by the combination of Codeine and Clomipramine. Depression [6A70-6A7Z] [87]
Trazodone DMK1GBJ Moderate Additive serotonergic effects by the combination of Codeine and Trazodone. Depression [6A70-6A7Z] [87]
Amitriptyline DMK7F9S Moderate Additive serotonergic effects by the combination of Codeine and Amitriptyline. Depression [6A70-6A7Z] [87]
Amoxapine DMKITQE Moderate Additive serotonergic effects by the combination of Codeine and Amoxapine. Depression [6A70-6A7Z] [87]
Mirtazapine DML53ZJ Moderate Additive serotonergic effects by the combination of Codeine and Mirtazapine. Depression [6A70-6A7Z] [87]
Protriptyline DMNHTZI Moderate Additive serotonergic effects by the combination of Codeine and Protriptyline. Depression [6A70-6A7Z] [87]
Doxepin DMPI98T Moderate Additive serotonergic effects by the combination of Codeine and Doxepin. Depression [6A70-6A7Z] [87]
Maprotiline DMPWB7T Moderate Additive serotonergic effects by the combination of Codeine and Maprotiline. Depression [6A70-6A7Z] [87]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Codeine and Esketamine. Depression [6A70-6A7Z] [92]
Hyoscyamine DM804UR Moderate Additive antimotility effects by the combination of Codeine and Hyoscyamine. Digestive system disease [DE2Z] [81]
Mepenzolate DM8YU2F Moderate Additive antimotility effects by the combination of Codeine and Mepenzolate. Digestive system disease [DE2Z] [81]
5-hydroxy-L-tryptophan DMDWZGJ Moderate Additive CNS depression effects by the combination of Codeine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [87]
Oxybutynine DMJPBAX Moderate Additive antimotility effects by the combination of Codeine and Oxybutynine. Discovery agent [N.A.] [81]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Codeine and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [86]
Trihexyphenidyl DMB19L8 Moderate Additive CNS depression effects by the combination of Codeine and Trihexyphenidyl. Dystonic disorder [8A02] [93]
Fenfluramine DM0762O Moderate Decreased metabolism of Codeine caused by Fenfluramine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [85]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Codeine and Diazepam. Epilepsy/seizure [8A61-8A6Z] [80]
Primidone DM0WX6I Major Additive CNS depression effects by the combination of Codeine and Primidone. Epilepsy/seizure [8A61-8A6Z] [80]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Codeine and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [94]
Stiripentol DMMSDOY Moderate Decreased metabolism of Codeine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [95]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Codeine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Codeine and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [80]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Codeine and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [80]
Carbamazepine DMZOLBI Moderate Increased metabolism of Codeine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Codeine and Dantrolene. Fever [MG26] [80]
Solifenacin DMG592Q Moderate Additive antimotility effects by the combination of Codeine and Solifenacin. Functional bladder disorder [GC50] [81]
Mirabegron DMS1GYT Moderate Decreased metabolism of Codeine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [85]
Tolterodine DMSHPW8 Moderate Additive antimotility effects by the combination of Codeine and Tolterodine. Functional bladder disorder [GC50] [81]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Codeine caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [85]
Terbinafine DMI6HUW Moderate Decreased metabolism of Codeine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [85]
Propantheline DM2EN6G Moderate Additive antimotility effects by the combination of Codeine and Propantheline. Gastric ulcer [DA60] [81]
Cimetidine DMH61ZB Moderate Decreased metabolism of Codeine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [85]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Codeine and Brimonidine. Glaucoma [9C61] [96]
Rifampin DMA8J1G Moderate Increased metabolism of Codeine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [83]
Rifapentine DMCHV4I Moderate Increased metabolism of Codeine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [83]
Delavirdine DM3NF5G Moderate Decreased metabolism of Codeine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Codeine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Efavirenz DMC0GSJ Moderate Increased metabolism of Codeine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Etravirine DMGV8QU Moderate Increased metabolism of Codeine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Ritonavir DMU764S Moderate Decreased metabolism of Codeine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Codeine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [85]
Givosiran DM5PFIJ Moderate Decreased metabolism of Codeine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [85]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Codeine and Belladonna. Infectious gastroenteritis/colitis [1A40] [81]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Codeine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [97]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Codeine and Suvorexant. Insomnia [7A00-7A0Z] [80]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Codeine and Amobarbital. Insomnia [7A00-7A0Z] [80]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Codeine and Ramelteon. Insomnia [7A00-7A0Z] [80]
Eszopiclone DM8RZ9H Major Additive CNS depression effects by the combination of Codeine and Eszopiclone. Insomnia [7A00-7A0Z] [80]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Codeine and Flurazepam. Insomnia [7A00-7A0Z] [80]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Codeine and Triazolam. Insomnia [7A00-7A0Z] [80]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Codeine and Zaleplon. Insomnia [7A00-7A0Z] [80]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Codeine and Propiomazine. Insomnia [7A00-7A0Z] [80]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Codeine and Tasimelteon. Insomnia [7A00-7A0Z] [80]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Codeine and Paraldehyde. Insomnia [7A00-7A0Z] [80]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Codeine and ITI-007. Insomnia [7A00-7A0Z] [80]
Zolpidem DMWOSKJ Major Additive CNS depression effects by the combination of Codeine and Zolpidem. Insomnia [7A00-7A0Z] [80]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Codeine and Quazepam. Insomnia [7A00-7A0Z] [80]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Codeine and Estazolam. Insomnia [7A00-7A0Z] [80]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Codeine and Clidinium. Irritable bowel syndrome [DD91] [81]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Codeine and Dicyclomine. Irritable bowel syndrome [DD91] [81]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Codeine and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [80]
PF-06463922 DMKM7EW Moderate Increased metabolism of Codeine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [83]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Codeine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [85]
Lumefantrine DM29GAD Moderate Decreased metabolism of Codeine caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [98]
Meprobamate DMHM93Y Major Additive CNS depression effects by the combination of Codeine and Meprobamate. Malaria [1F40-1F45] [80]
Halofantrine DMOMK1V Moderate Decreased metabolism of Codeine caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [85]
Chloroquine DMSI5CB Moderate Decreased metabolism of Codeine caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [85]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Codeine caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [85]
Quinine DMSWYF5 Moderate Decreased metabolism of Codeine caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [85]
Primaquine DMWQ16I Moderate Decreased metabolism of Codeine caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [85]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Codeine caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [85]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Codeine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [83]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Codeine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [99]
Almogran DM7I64Z Moderate Additive serotonergic effects by the combination of Codeine and Almogran. Migraine [8A80] [87]
Frovatriptan DM7RE8P Moderate Additive serotonergic effects by the combination of Codeine and Frovatriptan. Migraine [8A80] [87]
Rizatriptan DMDJMA3 Moderate Additive serotonergic effects by the combination of Codeine and Rizatriptan. Migraine [8A80] [87]
Naratriptan DMO50U2 Moderate Additive serotonergic effects by the combination of Codeine and Naratriptan. Migraine [8A80] [87]
Sumatriptan DMVYXR8 Moderate Additive serotonergic effects by the combination of Codeine and Sumatriptan. Migraine [8A80] [87]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Codeine and Lasmiditan. Migraine [8A80] [100]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Codeine and Flibanserin. Mood disorder [6A60-6E23] [101]
Panobinostat DM58WKG Moderate Decreased metabolism of Codeine caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [85]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Codeine and Thalidomide. Multiple myeloma [2A83] [102]
Carisoprodol DMWR1JC Major Additive CNS depression effects by the combination of Codeine and Carisoprodol. Musculoskeletal disorder [FA00-FC0Z] [80]
Rifabutin DM1YBHK Moderate Increased metabolism of Codeine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [83]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Codeine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [85]
Nilotinib DM7HXWT Moderate Decreased metabolism of Codeine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [85]
Imatinib DM7RJXL Moderate Decreased metabolism of Codeine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [85]
Prasugrel DM7MT6E Moderate Altered absorption of Codeine due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [103]
Modafinil DMYILBE Minor Increased metabolism of Codeine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [104]
Droperidol DM0DXA8 Major Additive cardiorespiratory depression effects by the combination of Codeine and Droperidol. Nausea/vomiting [MD90] [105]
Rolapitant DM8XP26 Moderate Decreased metabolism of Codeine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [85]
Palonosetron DMBHMOX Moderate Additive serotonergic effects by the combination of Codeine and Palonosetron. Nausea/vomiting [MD90] [87]
Metoclopramide DMFA5MY Moderate Additive CNS depression effects by the combination of Codeine and Metoclopramide. Nausea/vomiting [MD90] [106]
Dolasetron DMMG26Z Moderate Additive serotonergic effects by the combination of Codeine and Dolasetron. Nausea/vomiting [MD90] [87]
Ondansetron DMOTQ1I Moderate Additive serotonergic effects by the combination of Codeine and Ondansetron. Nausea/vomiting [MD90] [87]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Codeine and Bupropion. Nicotine use disorder [6C4A] [82]
Sibutramine DMFJTDI Moderate Additive serotonergic effects by the combination of Codeine and Sibutramine. Obesity [5B80-5B81] [87]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Codeine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [85]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Codeine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [85]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Codeine and Levomethadyl Acetate. Opioid use disorder [6C43] [86]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Codeine and Apraclonidine. Optic nerve disorder [9C40] [96]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Codeine and Biperiden. Parkinsonism [8A00] [93]
Procyclidine DMHFJDT Moderate Additive CNS depression effects by the combination of Codeine and Procyclidine. Parkinsonism [8A00] [93]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Codeine and Pimavanserin. Parkinsonism [8A00] [80]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Codeine and Orphenadrine. Parkinsonism [8A00] [80]
Abametapir DM2RX0I Moderate Decreased metabolism of Codeine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [107]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Codeine and Lindane. Pediculosis [1G00] [108]
Methylscopolamine DM5VWOB Moderate Additive antimotility effects by the combination of Codeine and Methylscopolamine. Peptic ulcer [DA61] [81]
Lefamulin DME6G97 Moderate Decreased metabolism of Codeine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [109]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Codeine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [85]
Enzalutamide DMGL19D Moderate Increased metabolism of Codeine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [83]
Levomepromazine DMIKFEL Moderate Decreased metabolism of Codeine caused by Levomepromazine mediated inhibition of CYP450 enzyme. Psychotic disorder [6A20-6A25] [85]
Fluphenazine DMIT8LX Major Additive CNS depression effects by the combination of Codeine and Fluphenazine. Psychotic disorder [6A20-6A25] [110]
Triflupromazine DMKFQJP Major Additive CNS depression effects by the combination of Codeine and Triflupromazine. Psychotic disorder [6A20-6A25] [80]
Bosentan DMIOGBU Moderate Increased metabolism of Codeine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [83]
Celecoxib DM6LOQU Moderate Decreased metabolism of Codeine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [85]
Dexamethasone DMMWZET Moderate Increased metabolism of Codeine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [83]
Nafcillin DMN9RPO Moderate Increased metabolism of Codeine caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [83]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Codeine caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [85]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Codeine and Quetiapine. Schizophrenia [6A20] [110]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Codeine and Mesoridazine. Schizophrenia [6A20] [110]
Thioridazine DM35M8J Major Additive CNS depression effects by the combination of Codeine and Thioridazine. Schizophrenia [6A20] [80]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Codeine and Aripiprazole. Schizophrenia [6A20] [80]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Codeine and Iloperidone. Schizophrenia [6A20] [80]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Codeine and Paliperidone. Schizophrenia [6A20] [80]
Loxapine DM8AI9U Major Additive CNS depression effects by the combination of Codeine and Loxapine. Schizophrenia [6A20] [110]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Codeine and Perphenazine. Schizophrenia [6A20] [80]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Codeine and Molindone. Schizophrenia [6A20] [80]
Chlorpromazine DMBGZI3 Major Additive CNS depression effects by the combination of Codeine and Chlorpromazine. Schizophrenia [6A20] [110]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Codeine and Thiothixene. Schizophrenia [6A20] [110]
Clozapine DMFC71L Major Additive CNS depression effects by the combination of Codeine and Clozapine. Schizophrenia [6A20] [110]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Codeine and Trifluoperazine. Schizophrenia [6A20] [80]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Codeine and Risperidone. Schizophrenia [6A20] [80]
Olanzapine DMPFN6Y Major Additive CNS depression effects by the combination of Codeine and Olanzapine. Schizophrenia [6A20] [110]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Codeine and Asenapine. Schizophrenia [6A20] [80]
Pimozide DMW83TP Major Additive CNS depression effects by the combination of Codeine and Pimozide. Schizophrenia [6A20] [80]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Codeine and Fentanyl. Sensation disturbance [MB40] [80]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Codeine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [83]
Armodafinil DMGB035 Minor Increased metabolism of Codeine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [104]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Codeine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [111]
Brilinta DMBR01X Moderate Altered absorption of Codeine due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [103]
Clopidogrel DMOL54H Moderate Altered absorption of Codeine due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [103]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Codeine and Tizanidine. Tonus and reflex abnormality [MB47] [80]
Atropine DMEN6X7 Moderate Additive antimotility effects by the combination of Codeine and Atropine. Unspecific substance harmful effect [NE6Z] [81]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Codeine and Cetirizine. Vasomotor/allergic rhinitis [CA08] [112]
Propafenone DMPIBJK Moderate Decreased metabolism of Codeine caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [85]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Codeine caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [85]
⏷ Show the Full List of 191 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Codeine 15 mg tablet 15 mg Oral Tablet Oral
Codeine 30 mg tablet 30 mg Oral Tablet Oral
Codeine 60 mg tablet 60 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1673).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074256.
3 Effects of a mu-opioid receptor agonist (codeine phosphate) on visuo-motor coordination and dynamic visual acuity in man. Br J Clin Pharmacol. 1986 Nov;22(5):507-12.
4 BDDCS applied to over 900 drugs
5 Chen ZR, Somogyi AA, Reynolds G, Bochner F: Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol. 1991 Apr;31(4):381-90.
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
11 Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2015 May;64(5):1786-93.
12 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
13 Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
14 Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33.
15 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
16 Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4.
17 Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol. 2012 May;73(5):786-94.
18 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
19 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
20 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
21 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
22 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
23 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
24 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
25 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
26 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
27 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
28 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
29 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
30 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
31 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
32 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
33 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
34 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
35 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
36 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
37 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
38 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
39 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
40 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
41 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
42 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
43 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
44 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
45 Drug Interactions Flockhart Table
46 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
47 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
48 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
49 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
50 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
51 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
52 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
53 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
54 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
55 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
56 Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica. 2008 Jan;38(1):62-75.
57 Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28.
58 Adult and infant pharmacokinetic profiling of dihydrocodeine using physiologically based pharmacokinetic modeling. Biopharm Drug Dispos. 2019 Nov;40(9):350-357.
59 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
60 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
61 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
62 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
63 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
64 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
65 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
66 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
67 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
68 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
69 Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
70 Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
71 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
72 Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
73 Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
74 Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381.
75 Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
76 Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
77 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
78 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
79 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
80 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
81 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
82 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
83 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
84 Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
85 Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
86 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
87 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
88 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
89 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
90 Sturner WQ, Garriott JC "Deaths involving propoxyphene: a study of 41 cases over a two-year period." JAMA 223 (1973): 1125-30. [PMID: 4739371]
91 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
92 Cerner Multum, Inc. "Australian Product Information.".
93 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
94 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
95 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
96 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
97 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
98 Caraco Y, Sheller J, Wood JJ "Pharmacogenetic determination of the effects of codeine and prediction of drug interactions." J Pharmacol Exp Ther 278 (1996): 1165-74. [PMID: 8819499]
99 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
100 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
101 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
102 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
103 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
104 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
105 Canadian Pharmacists Association.
106 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
107 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
108 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
109 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
110 Cerner Multum, Inc. "Canadian Product Information.".
111 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
112 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.